A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
該当なし
早期終了
NCT05966740
| 対象疾患 | Venous Thromboembolism |
|---|
| 相 | 該当なし |
|---|
| スポンサー | Boehringer Ingelheim |
|---|
| ステータス | 早期終了 |
|---|
| 参加者数 | 5 名 |
|---|
| 開始日 | 2024年4月19日 |
|---|
| 完了日 | 2025年4月28日 |
|---|
| 結果公開日 | 2026年6月2日 |
|---|
概要
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Cumulative Incidence of Clinically Relevant Bleeding Events
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days. · Participants
| Pradaxa-treated Patients | 1 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。